Ozempic
Ozempic is the brand name of subcutaneous semaglutide manufactured by Novo Nordisk, FDA-approved in 2017 for the treatment of type 2 diabetes. It is administered once weekly at doses of 0.25 mg, 0.5 mg, 1 mg, or 2 mg via prefilled pen injector. Ozempic is not FDA-approved for weight loss; the same molecule at a higher dose is sold as Wegovy for chronic weight management.
What is Ozempic?
Ozempic is the brand name of semaglutide marketed by Novo Nordisk for the treatment of type 2 diabetes. It received FDA approval in December 2017 and has since become one of the most prescribed medications globally.
Ozempic is delivered as a once-weekly subcutaneous injection from a prefilled pen device. Available doses:
- 0.25 mg / week (initiation only, weeks 1-4)
- 0.5 mg / week
- 1 mg / week
- 2 mg / week (maximum approved)
A separate semaglutide product, Wegovy, contains the same molecule at higher maximum dose (2.4 mg/week) and is FDA-approved for chronic weight management. Ozempic is not FDA-approved for weight loss — its widely reported weight loss effects in non-diabetic users represent off-label prescribing.
How is Ozempic used?
For type 2 diabetes, Ozempic is approved as adjunct to diet and exercise to improve glycemic control, and additionally to reduce major adverse cardiovascular events in adults with T2D and established cardiovascular disease.
The standard titration schedule is:
- Weeks 1-4: 0.25 mg/week (acclimation; not therapeutic)
- Week 5+: 0.5 mg/week
- After ≥4 weeks at 0.5 mg, may escalate to 1 mg
- After ≥4 weeks at 1 mg, may escalate to 2 mg
Slower titration substantially reduces GI side effects.
Why Ozempic matters for nutrition
Patients on Ozempic experience the same nutrition concerns as those on any GLP-1 receptor agonist:
- Protein adequacy at reduced total intake (1.2-1.6 g/kg/day)
- Resistance training to preserve lean mass
- Hydration and electrolytes during GI symptoms
- Slow re-introduction of food volume during titration
- Consideration of multivitamin if intake remains low for months
Common side effects from clinical trials: nausea (15-20%), vomiting (5-10%), diarrhea (10%), constipation (5%), fatigue. Rare: pancreatitis, gallbladder events, retinopathy progression in T2D. Boxed warning for thyroid C-cell tumors.
This is general educational information, not medical advice. Consult your physician before starting, stopping, or adjusting Ozempic. Whether Ozempic is appropriate for you, what dose to use, and how to manage side effects are decisions for your prescribing clinician.
See semaglutide, Mounjaro, and GLP-1 receptor agonist for related entries.